Helus Pharma (NASDAQ: HELP) (Cboe CA: HELP), a clinical-stage pharmaceutical company developing novel serotonergic agonists (NSAs), announced that its Chief Medical Officer, Amir Inamdar, will participate in a fireside chat at the H.C. Wainwright 7th Annual Neuro Perspectives Hybrid Conference. The conference is scheduled for June 15-16, 2026, with the fireside chat available on demand beginning June 15 at 7:00 a.m. EDT. This event provides a platform for Helus Pharma to discuss its proprietary NSAs, which are synthetic molecules designed to activate serotonin pathways believed to promote neuroplasticity.
The company's lead candidate, HLP003, is in Phase 3 clinical development for the adjunctive treatment of major depressive disorder and has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration. Additionally, HLP004 is in Phase 2 for generalized anxiety disorder. Helus Pharma aims to address the large unmet need for people suffering from depression, anxiety, and other mental health conditions through these innovative treatments.
The participation of Dr. Inamdar at this conference underscores the importance of Helus Pharma's research and development efforts. The fireside chat is expected to provide insights into the company's clinical programs and the potential impact of NSAs on mental health treatment. For more details, the full press release is available at https://ibn.fm/KsnJW.
Helus Pharma, the commercial operating name of Cybin Inc., operates in Canada, the United States, the United Kingdom, and Ireland. The company has an extensive research portfolio of investigational NSAs and is committed to improving the treatment landscape for mental health conditions. Investors and stakeholders can find the latest news and updates at https://ibn.fm/HELP.
